Segall Bryant & Hamill LLC Purchases 41,238 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Segall Bryant & Hamill LLC boosted its stake in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 40.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 142,039 shares of the company's stock after acquiring an additional 41,238 shares during the period. Segall Bryant & Hamill LLC owned 0.27% of PROCEPT BioRobotics worth $11,437,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of PRCT. Vanguard Group Inc. grew its position in shares of PROCEPT BioRobotics by 6.1% during the fourth quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock valued at $413,907,000 after purchasing an additional 297,075 shares in the last quarter. State Street Corp grew its holdings in PROCEPT BioRobotics by 5.9% during the 3rd quarter. State Street Corp now owns 1,179,514 shares of the company's stock valued at $94,503,000 after buying an additional 66,175 shares in the last quarter. Geode Capital Management LLC increased its stake in PROCEPT BioRobotics by 8.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,106,588 shares of the company's stock worth $88,678,000 after acquiring an additional 84,244 shares during the last quarter. Franklin Resources Inc. increased its stake in PROCEPT BioRobotics by 64.5% in the 3rd quarter. Franklin Resources Inc. now owns 885,992 shares of the company's stock worth $64,669,000 after acquiring an additional 347,330 shares during the last quarter. Finally, Perpetual Ltd purchased a new stake in shares of PROCEPT BioRobotics during the 4th quarter worth approximately $66,972,000. 89.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total value of $312,403.50. Following the completion of the sale, the chief executive officer now directly owns 173,070 shares of the company's stock, valued at $9,875,374.20. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Kevin Waters sold 733 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now directly owns 107,991 shares in the company, valued at approximately $6,161,966.46. This trade represents a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,455 shares of company stock valued at $368,322 in the last quarter. 17.40% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on PRCT shares. Morgan Stanley cut their target price on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Wells Fargo & Company restated an "overweight" rating and issued a $112.00 target price on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Finally, Truist Financial reaffirmed a "buy" rating and issued a $90.00 price target (down previously from $105.00) on shares of PROCEPT BioRobotics in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $94.29.

PROCEPT BioRobotics Trading Down 2.8 %

Shares of PROCEPT BioRobotics stock traded down $1.71 during trading on Friday, hitting $60.05. The stock had a trading volume of 823,605 shares, compared to its average volume of 750,377. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.02 and a quick ratio of 5.07. PROCEPT BioRobotics Co. has a 12 month low of $45.56 and a 12 month high of $103.81. The stock has a market cap of $3.29 billion, a PE ratio of -30.79 and a beta of 1.05. The firm's fifty day simple moving average is $65.34 and its 200-day simple moving average is $77.82.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. The business had revenue of $68.24 million for the quarter, compared to analysts' expectations of $66.79 million. As a group, sell-side analysts expect that PROCEPT BioRobotics Co. will post -1.75 EPS for the current fiscal year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).